Ozempic vs Mounjaro: A Field Guide to the Incretin Category

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The PlexusDx Education Hub is where GLP-1 therapies, weight-management protocols, and the genetics behind them are explained in plain language. Visit the Peptides & GLP-1 library.

This is an independent editorial overview. PlexusDx has no commercial relationship with the manufacturers of any product named on this page.

Comparing Ozempic and Mounjaro is really an invitation to understand the whole incretin category around them. Rather than crown a winner, this overview maps the family of GLP-1 pathway compounds available as of April 2026 — how they are built, when they were approved, what was studied, and the genetics that underlie every one of them.

Mapping the incretin category in 2026

Ozempic (semaglutide, Novo Nordisk) and Mounjaro (tirzepatide, Eli Lilly) are both GLP-1 pathway compounds, but they anchor different branches of a growing family. Placing them next to their relatives makes the category legible instead of reducing it to a two-way contest.

Receptor targets across the family

GLP-1-selective agents

Semaglutide, liraglutide, and dulaglutide engage the GLP-1 receptor alone, all modulating gastric emptying, post-meal glucose, and satiety signaling.

Dual GIP and GLP-1 agents

Tirzepatide adds agonism at the GIP receptor alongside GLP-1, the design that defines the dual-agonist branch of the category.

Investigational triple agonists

Retatrutide is an investigational GLP-1, GIP, and glucagon triple agonist that is not FDA-approved as of April 2026 and is not sold by PlexusDx.

A timeline of FDA approvals

Approvals depend on indication: Ozempic (semaglutide) for type 2 diabetes in 2017; Wegovy (semaglutide 2.4 mg) for chronic weight management in 2021; Rybelsus (oral semaglutide) for type 2 diabetes in 2019; Mounjaro (tirzepatide) for type 2 diabetes in 2022; Zepbound (tirzepatide) for chronic weight management in 2023 and obstructive sleep apnea in 2024; Trulicity (dulaglutide) in 2014; Victoza (liraglutide) in 2010.

What the major trial programs tested

The evidence base spans several programs: STEP (semaglutide for weight management), SUSTAIN and SELECT (semaglutide for diabetes and cardiovascular outcomes), SURMOUNT and SURPASS (tirzepatide), SURMOUNT-OSA (tirzepatide for sleep apnea), LEAD and LEADER (liraglutide), and AWARD (dulaglutide). Head-to-head data exists for some pairings, including SUSTAIN 7 and SURPASS-2, but populations and endpoints differ, so per-trial reading is best.

The safety framework that spans the class

Every FDA-approved GLP-1 and GIP/GLP-1 agent carries the class boxed warning for thyroid C-cell tumor risk seen in rodent studies and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Gastrointestinal effects are most common; rare serious events include pancreatitis, gallbladder disease, and dehydration-related kidney injury.

How list pricing spreads across brands

As of April 2026, list prices for the FDA-approved brands range roughly $815–$1,620 per month at U.S. list price (manufacturer published pricing). What a patient actually pays depends heavily on insurance coverage, the FDA indication on the prescription, manufacturer savings-card eligibility, and compounded-alternative availability through licensed compounding pathways.

Genes that map the metabolic terrain

Underneath every product in this family, the genetic architecture is shared. Variants in FTO (appetite and adiposity set-point), GLP1R (the receptor every GLP-1 compound engages), MC4R (energy balance), and TCF7L2 (glucose homeostasis and GLP-1 secretion) map the terrain any compound works on. These pathway-level variants describe biology; they do not predict response to a specific drug.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. Before any protocol begins, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including FTO, MC4R, and TCF7L2 — so you enter the conversation with upstream context rather than guesswork.

Disclaimer: This article is educational. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, and this page covers the mechanism, evidence, and genetic context that inform any decision to use them. PlexusDx does not sell, prescribe, or recommend any other GLP-1 category peptide beyond semaglutide and tirzepatide, including dulaglutide, liraglutide, retatrutide, and cagrilintide. The Precision Peptide Genetic Test does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Start with the biology. Take the Precision Peptide Genetic Test, or explore the Weight Management Protocols.

Frequently Asked Questions about Ozempic and Mounjaro

How many GLP-1 products are in this category?

The FDA-approved family includes semaglutide brands (Ozempic, Wegovy, Rybelsus), tirzepatide brands (Mounjaro, Zepbound), dulaglutide (Trulicity), and liraglutide (Victoza), among others. Retatrutide, a triple agonist, remains investigational. Ozempic and Mounjaro are two anchors within a broader lineup rather than the only two options a clinician considers.

Where does a dual agonist fit versus a selective one?

Selective agents such as semaglutide engage only the GLP-1 receptor, while dual agents such as tirzepatide add the GIP receptor. Both branches sit inside the same incretin category. The distinction reflects molecular design chosen during development, and it shapes how each compound is studied and prescribed.

Does the genetic test cover this whole category?

The Precision Peptide Genetic Test analyzes pathway-level variants like FTO and MC4R, and TCF7L2 that underlie the entire GLP-1 pathway, not a single brand. It does not predict response to Ozempic, Mounjaro, or any product; it describes the baseline biology every compound in the family has to act on.

Why do list prices vary so widely across brands?

The roughly $815–$1,620 monthly spread reflects manufacturer pricing decisions tied to each brand and indication, not a ranking of effectiveness. Actual cost depends on insurance coverage, the indication on the prescription, savings-card eligibility, and whether a compounded pathway is available for a given compound.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.